Neonatal Medicine

  • 제16권2호
  • /
  • Pages.101-109
  • /
  • 2009
  • /
  • 2287-9412(pISSN)
  • /
  • 2287-9803(eISSN)
대한신생아학회 (The Korean Society of Neonatology)
권호 표지

신생아 호흡곤란증후군에서 인공 폐 표면활성제 조기요법의 중요성과 필요성

The Importance and the Need of Early Pulmonary Surfactant Therapy in Premature Infant with Respiratory Distress Syndrome

  • 김성미 (부산성모병원 소아청소년과) ;
  • 윤혜선 (을지의대 노원을지병원 소아청소년과) ;
  • 김기수 (울산의대 서울아산병원 소아청소년과) ;
  • 배종우 (경희의대 동서신의학병원 소아청소년과)
  • Kim, Sung-Mi (Department of Pediatrics, Busan St. Mary's Medical Center) ;
  • Yoon, Hye-Sun (Department of Pediatrics, Eulji University School of Medicine) ;
  • Kim, Ki-Soo (Department of Pediatrics, Asan Medical Center, Ulsan University) ;
  • Bae, Chong-Woo (Department of Pediatrics, Kyunghee University East-West Medical Center)
  • 발행 : 2009.11.30

⟨ 이전 논문 다음 논문 ⟩

초록

Pulmonary surfactant (PS) therapy in premature infants has a remarkable impact on improving survival and outcomes in neonatal respiratory distress syndrome (RDS). Early PS therapy involves instillation of PS upon delivery of very premature infants or if there is evidence of RDS, such as an increased requirement of oxygen 2 hours after birth, especially in infants <30 weeks gestation. Early PS treatment in very premature infants results in a significant reduction in the severity of RDS, mortality, and incidence of pneumothorax, pulmonary interstitial emphysema, and bronchopulmonary dysplasia in comparison with late PS treatment. According to European and American consensus guidelines on the management of neonatal RDS, early PS instillation should be considered for infants <30 weeks gestation, infants with a birth weight <1,250 g, or if the mother has not received antepartum corticosteroids. We suggest that the Korean health insurance policy on RDS be modified so that PS can be used for better clinical outcomes of very premature infants.

키워드

참고문헌

  1. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. AMA J Dis Child 1959;97:517-23.
  2. Taeusch HW, Ramierez-Schrempp D, Laing IA. Surfactant treatment of respiratoy disorders. In: Taeusch HW,Ballard RA, Gleason CA, editors. Avery's diseases of the newborn. 8th ed. Philadellphia: WB Saunders Co, 2005:670-85.
  3. Vermont Oxford Network 1996 Database Summary, 1997 Vermont Oxford Network, email:mail@vtoxoford.org
  4. Dudell GG, Stoll BJ. Respiratory tract disorders. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF, editors. Nelson textbook of pediatrics, 18th ed. Philadelphia: WB Saunders Co, 2007:728-53.
  5. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006;3:CD004454.
  6. Welty S, Hansen TN, Corbet A. Respiratory distress in the preterm infant. In: Taeusch HW, Ballard RA, Gleason CA, editors. Avery's diseases of the newborn. 8th ed. Philadelphia: WB Saunders Co, 2005:687-703.
  7. Engle WA. American Academy of Pediatrics Committee on Fetus and Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics 2008;121:419-32.
  8. Bae CW. Hahn WH. Surfactant therapy for neonatal respiratory distress syndrome: A review of Korean experiences over 17 years. J Korean Med Sci 2009; 24: 1110-8. https://doi.org/10.3346/jkms.2009.24.6.1110
  9. Bae CW. Surfactant replacement therapy in RDS: A collaborative study of multi-center trials in Korea. J Korean Soc Neonatol 1997;4:124-35.
  10. Bae CW, Kim YM. Surfactant therapy for neonatal respiratory distress syndrome: experience in Korea over 15 Years. Korean J Pediatr 2004:47:940-8.
  11. Jobe AH. Pulmonary surfactant therapy. N Engl J Med 1993;328:861-8. https://doi.org/10.1056/NEJM199303253281208
  12. Fujiwara T, Konishi M, Chida S, Okuyama K, Ogawa Y, Takeuchi Y, et al. Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome; final analysis of a multicenter, double-blind, randomized trial and comparison with similar trials. Pediatrics 1990;86:753-64.
  13. Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2000;2:CD000511.
  14. Soll RF, Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2001;2:CD000510.
  15. Stevens TP, Harrington EW, Blennow M, Soll RF. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev 2007;4:CD003063.
  16. Shimada S, Chida S, Fujiwara T, Konishi M, Ogawa Y, Okuyama K, et al. Prophylactic versus rescue administration of surfactant-TA for respiratory distress syndrome: A multicenter randomized clinical trial. J Jpn Pediatr 2002:106:1251-60.
  17. Plavka R, Kopecky P, Sebron V, Leiska A, Svihovec P, Ruffer J, et al. Early versus delayed surfactant administration in extremely premature neonates with respiratory distress syndrome ventilated by high-frequency oscillatory ventilation. Intensive Care Med 2002;28:1483-90. https://doi.org/10.1007/s00134-002-1440-1
  18. Dani C, Bertini G, Pezzati M, Cecchi A, Caviglioli C, Rubaltelli FF. Early extubation and nasal continuous positive airway pressure after surfactant treatment for respiratory distress syndrome among preterm infants <30 weeks' gestation. Pediatrics 2004;113:e560-3. https://doi.org/10.1542/peds.113.6.e560
  19. Reininger A, Khalak R, Kendig JW, Ryan RM, Stevens TP, Reubens L, et al. Surfactant administration by transient intubation in infants 29 to 35 weeks' gestation with respiratory distress syndrome decreases the likelihood of later mechanical ventilation: a randomized controlled trial. J Perinatol 2005;25:703-8. https://doi.org/10.1038/sj.jp.7211381
  20. Egberts J, de Winter JP, Sedin G, de Kleine MJ, Broberger U, van Bel F, et al. Comparison of prophylaxis and rescue treatment with Curosurf in neonates less than 30 weeks' gestation: a randomized trial. Pediatrics 1993;92:768-74.
  21. Rojas MA, Lozano JM, Rojas MX, Laughon M, Bose CL, Rondon MA, et al. Very early surfactant without mandatory ventilation in premature infants treated with early continuous positive airway pressure: a randomized, controlled trial. Pediatrics 2009;123:137-42. https://doi.org/10.1542/peds.2007-3501
  22. Brown DR, Bloom BT, Cohen M, Myers MM, Egan EA, Kattwinkel J, et al. Increased survival in low birth weight neonates given prophylactic surfactant. J Perinatol 1998; 18:431-5.
  23. Kattwinkel J, Bloom BT, Delmore P, Davis CL, Farrell E, Friss H, et al. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation. Pediatrics 1993;92:90-8.
  24. Kendig JW, Notter RH, Cox C, Reubens LJ, Davis JM, Maniscalco WM, et al. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation. N Engl J Med 1991; 324:865-71. https://doi.org/10.1056/NEJM199103283241301
  25. Sweet D, Bevilacqua G, Carnielli V, Greisen G, Plavka R, Didrik Saugstad O, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome. J Perinat Med 2007;35:175-86. https://doi.org/10.1515/JPM.2007.048
  26. Escobedo MB, Gunkel JH, Kennedy KA, Shattuck KE, Sanchez PJ, Seidner S, et al. Early surfactant for neonates with mild to moderate respiratory distress syndrome: a multicenter, randomized trial. J Pediatr 2004;144:804-8.
  27. Bae CW. Neonatal viability, morbidity, mortality and outcome of very low birth weight infant. Korean J Pediatr 2000:43:1-12.
  28. Kim KS, Bae CW. Trends in survival rate for very low birth weight infants and extremely low birth weight infants in Korea, 1967-2007. Korean J Pediatr 2008;51:237-42. https://doi.org/10.3345/kjp.2008.51.3.237